The ALINA trials demonstrated that adjuvant alectinib significantly improved DFS as compared with platinum‐based chemotherapy among patients with resected ALK‐positive NSCLC of stage IB‐IIIA. The gene discussed is ALK; the disease is non-small cell lung carcinoma.